Trial Profile
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Citalopram/pipamperone (Primary) ; Citalopram; Pipamperone
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors PharmaNeuroBoost
- 31 Jan 2024 According to an ANeuroTech Media Release, company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01.
- 31 Jan 2024 According to an ANeuroTech Media Release, data from this study was published in the journal of Personalized Medicine in Psychiatry.
- 31 Jan 2024 Results presented in an ANeuroTech Media Release.